Clinical Trial Update: Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase I dose-escalation study of dihydromyricetin (DHM) for alcohol-associated liver disease, with recruitment not yet st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcoholic Liver Disease

Drugs mentioned

• Dihydromyricetin (dihydromyricetin)

Snippet

Sponsor: University of Southern California | Conditions: Alcohol-Related Disorders | Phase 1 | Status: NOT_YET_RECRUITING